Indole-3-carbinol prevents murine colitis development via an IL-22-dependent mechanism that regulates anti-microbial peptides and mucus production

Philip Brandon Busbee,Haider Alrafas,Nicholas Dopkins,Mitzi Nagarkatti,Prakash S Nagarkatti
DOI: https://doi.org/10.4049/jimmunol.202.supp.192.12
2019-05-01
The Journal of Immunology
Abstract:Abstract Colitis is an inflammatory bowel disease characterized by acute or chronic inflammation within the colon. In our previous work, we showed that indole-3-carbinol (I3C), a naturally-occurring plant product found in a number of cruciferous vegetables, was able to prevent development of colitis in murine models. I3C prevented colitis-associated microbial dysbiosis characterized by an overabundance of potentially pathogenic gram-negative bacteria (e.g. Bacteroides acidifaciens), in addition to increasing anti-inflammatory gram-positive butyrate-producing species (e.g. Roseburia). This increase in butyrate by I3C, validated by metabolomics analysis, leads to a decrease in the pro-inflammatory T cell response (Th17) and an increase in anti-inflammatory Tregs, which was confirmed by sodium butyrate supplementation experiments. In the current study, we further defined the mechanisms by which I3C was able to prevent colitis-associated microbial dysbiosis and dysregulation of gut microbial metabolome by evaluating expression of key intestinal regulatory genes in immune cells and colonic epithelial cells (CECs). Transcriptome analysis and PCR validation of CECs showed mucus production (e.g. Muc2) and colonic anti-microbial peptides (e.g. beta-defensins) were significantly increased after I3C. I3C was also shown to, in a butyrate-independent manner, increase expression of colonic bacterial defensive interleukin-22 (IL-22) by epigenetic regulation. Lastly, in vivo IL-22 neutralization experiments negated the beneficial effects of I3C, thus proving this cytokine was crucial in I3C-mediated prevention of colitis development and regulation of key intestinal regulatory components such as mucus and AMP production.
immunology
What problem does this paper attempt to address?